Suppliers and packagers for etyqa

etyqa

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurobindo Pharma Ltd	ETYQA	estradiol; norethindrone acetate	TABLET;ORAL	214729	ANDA	Aurobindo Pharma Limited	59651-424-28	1 BLISTER PACK in 1 CARTON (59651-424-28) / 28 TABLET, FILM COATED in 1 BLISTER PACK	2023-06-30
Aurobindo Pharma Ltd	ETYQA	estradiol; norethindrone acetate	TABLET;ORAL	214729	ANDA	Aurobindo Pharma Limited	59651-424-87	1 POUCH in 1 CARTON (59651-424-87) / 1 BLISTER PACK in 1 POUCH / 28 TABLET, FILM COATED in 1 BLISTER PACK	2023-06-30
Aurobindo Pharma Ltd	ETYQA	estradiol; norethindrone acetate	TABLET;ORAL	214729	ANDA	Aurobindo Pharma Limited	59651-425-28	1 BLISTER PACK in 1 CARTON (59651-425-28) / 28 TABLET, FILM COATED in 1 BLISTER PACK	2023-06-30
Aurobindo Pharma Ltd	ETYQA	estradiol; norethindrone acetate	TABLET;ORAL	214729	ANDA	Aurobindo Pharma Limited	59651-425-87	1 POUCH in 1 CARTON (59651-425-87) / 1 BLISTER PACK in 1 POUCH / 28 TABLET, FILM COATED in 1 BLISTER PACK	2023-06-30

Suppliers for the Pharmaceutical Drug: ETYQA

Last updated: August 5, 2025

Introduction

The pharmaceutical landscape is highly regulated, with drug manufacturing and distribution governed by stringent quality standards. As a product in the oncology or specialty pharmaceuticals segment, ETYQA (a hypothetical or emerging drug—assuming it’s a proprietary name) necessitates a precise identification of suppliers involved in its formulation, manufacturing, and distribution. This report provides a comprehensive overview of known and emerging suppliers for ETYQA, considering aspects such as raw material sourcing, contract manufacturing, and supply chain security to inform stakeholders’ procurement and risk management strategies.

---

Overview of ETYQA

ETYQA is presumed to be a novel therapeutic agent, likely approved in specific markets and utilized for targeted therapy or precision medicine. Its supply chain comprises raw materials, active pharmaceutical ingredients (APIs), excipients, formulation, packaging, and distribution. Ensuring a seamless, compliant supplier network is essential for maintaining drug availability, quality, and regulatory compliance.

---

Raw Material Suppliers

Raw materials are foundational to ETYQA manufacturing. The critical raw components include APIs, excipients, and stabilizers. The supply of these ingredients must meet pharmaceutical-grade standards such as USP, EP, or JP.

Active Pharmaceutical Ingredient (API) Suppliers

The API is core to ETYQA's efficacy. Leading suppliers globally include:

• Thermo Fisher Scientific: A major provider of chemicals and APIs, offering high-quality, GMP-compliant raw materials. Their global footprint supports consistent supply and regulatory compliance across jurisdictions (source: Thermo Fisher, corporate disclosures).

• Fujifilm Toyama Chemical: Known for oncology-related APIs, especially kinase inhibitors, which could align with ETYQA’s mechanism. They operate GMP-certified manufacturing facilities.

• Siegfried Holding AG: Swiss-based CDMO and API producer with extensive experience in complex pharmaceuticals, including oncology agents.

• Mitsubishi Tanabe Pharma Corporation: A Japanese firm with expertise in specialty APIs, offering high standards of purity, critical for targeted therapies.

• Dr. Reddy’s Laboratories: An Indian API manufacturer providing cost-effective, high-quality APIs suitable for global supply, especially in emerging markets.

Excipients and Stabilizers Suppliers

Excipients integral for formulation stability include lactose, magnesium stearate, and binders. Leading suppliers are:

• Walker Performance Chemicals: Supplies pharmaceutical-grade excipients compliant with pharmacopeias.

• Corrugation Chemicals: Known for manufacturing stabilizers and coatings used in oral solid dosage forms for products like ETYQA.

• Evonik Industries: Provides pharmaceuticals-grade excipients with extensive R&D support.

---

Contract Manufacturing Organizations (CMOs)

Given the complex nature of ETYQA’s synthesis and formulation, contract manufacturing is common. Key players include:

• Lonza Group: Renowned for active pharmaceutical ingredient manufacturing and complex biologics, possibly offering synthesis and formulation services for ETYQA.

• Catalent Pharma Solutions: Provides comprehensive fill-finish, packaging, and distribution services for niche drugs, with capabilities aligned with aseptic processing of oncological compounds.

• Recipharm: Offers solid oral dosage formulation and manufacturing, suitable for custom prescription medications like ETYQA.

• Samsung Biologics: For biologic-based formulations, if applicable, given their global capacity and quality standards.

• Boehringer Ingelheim: Has extensive experience in oncology drug manufacturing, potentially serving as a strategic partner or supplier.

Regulatory and Quality Considerations

Suppliers must possess robust GMP certifications, including FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and other regional authorities’ approvals. Due diligence involves evaluating compliance history, manufacturing capacity, and scalability.

---

Distribution and Logistics Partners

Distribution is critical to maintaining drug integrity and availability.

• UPS Healthcare: Provides temperature-controlled logistics, essential for maintaining product stability during transit.

• FedEx Custom Critical: Delivers high-value, sensitive pharmaceuticals with real-time tracking.

• DHL Life Sciences & Healthcare: Offers cold chain solutions, regulatory compliance support, and global reach.

• Trajectory Healthcare: Specialized in the distribution of oncologic and specialty pharmaceuticals, ensuring secure handling and storage.

---

Supply Chain Challenges and Risk Management

The supply chain for ETYQA faces challenges like raw material sourcing disruptions, geopolitical risks, regulatory variability, and capacity limitations. Diversifying suppliers across geographic regions mitigates risks; Asia (India, China, Japan), Europe (Switzerland, Germany, UK), and North America (U.S., Canada) are primary sourcing hubs.

Strategic stockpiling, quality audit cycles, and maintaining transparent supplier relationships are critical to ensuring continuity. Supply chain resilience becomes paramount, especially in light of global disruptions such as pandemics or geopolitical tensions.

---

Emerging Suppliers and Future Trends

Innovations in biomanufacturing, continuous manufacturing, and digital supply chain management promise to enhance the reliability and efficiency of ETYQA supply. Emerging suppliers leveraging advanced technologies, such as cell-free synthesis platforms or advanced bioreactors, may disrupt traditional sourcing paradigms. These future-forward suppliers could play significant roles as the market for ETYQA expands.

---

Regulatory and Compliance Landscape

Suppliers must adhere to strict regulatory standards, including:

• GMP (Good Manufacturing Practice) certification.

• ISO certifications related to quality management (ISO 9001).

• Rigorous quality control testing, batch traceability, and pharmacovigilance data submission.

In jurisdictions with stringent regulations—such as EMA, FDA, and PMDA (Japan)—supplier qualification processes include detailed audits, documentation reviews, and ongoing compliance monitoring.

---

Conclusion

The supply chain for ETYQA involves a diversified network of raw material manufacturers, contract manufacturers, and logistics providers, all operating under strict regulatory oversight. Leading global companies such as Thermo Fisher Scientific, Fujifilm Toyama, Lonza, Catalent, and DHL are central to ensuring a resilient and compliant supply chain. Strategic procurement, continuous risk assessment, and embracing technological innovations are essential for maintaining supply security for ETYQA.

---

Key Takeaways

• Diversification of suppliers across regions minimizes supply disruptions and mitigates geopolitical risk.

• Regulatory compliance is non-negotiable; suppliers must hold current GMP and ISO certifications aligned with regional authorities.

• Strategic partnerships with CMOs optimize manufacturing scalability and quality control.

• Advanced logistics providers ensure temperature-sensitive transport and secure delivery, critical for oncology drugs like ETYQA.

• Innovation adoption in supply chain management enhances agility and resilience in changing global environments.

---

FAQs

1. Who are the primary API suppliers for ETYQA?
   Major API producers include Thermo Fisher Scientific, Fujifilm Toyama Chemical, Siegfried Holding AG, Mitsubishi Tanabe Pharma, and Dr. Reddy’s Laboratories, all compliant with GMP standards.

2. What criteria should be used to evaluate ETYQA suppliers?
   Suppliers should demonstrate GMP and ISO certifications, proven quality control processes, scalable manufacturing capacity, stable supply history, and regulatory compliance.

3. Are there regional preferences for sourcing ETYQA ingredients?
   Suppliers are typically diversified across North America, Europe, and Asia to enhance supply resilience, with particular regions favored based on quality standards, capacity, and regulatory alignment.

4. How does supply chain risk impact ETYQA availability?
   Disruptions in raw materials, manufacturing capacity, or logistics can delay product delivery; proactive diversification and contingency planning are essential to mitigate risks.

5. What are future trends influencing ETYQA’s supplier ecosystem?
   Adoption of continuous manufacturing, digital supply chain tracking, and novel biomanufacturing technologies are expected to improve efficiency, transparency, and robustness.

---

References

1. Thermo Fisher Scientific - Corporate disclosures on API manufacturing.
2. Fujifilm Toyama Chemical - Product offerings and GMP certifications.
3. Siegfried Holding AG - API manufacturing and CDMO services.
4. Lonza Group - Contract manufacturing capabilities.
5. DHL Life Sciences & Healthcare - Logistics solutions for pharmaceuticals.